Zacks Research Has Negative Estimate for Neogen Q3 Earnings

Neogen Corporation (NASDAQ:NEOG) – Analysts at Zacks Research dropped their Q3 2026 EPS estimates for shares of Neogen in a report released on Wednesday, December 17th. Zacks Research analyst Team now expects that the company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.08. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s Q3 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.07 EPS, FY2027 earnings at $0.30 EPS and Q1 2028 earnings at $0.09 EPS.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neogen in a report on Monday. Piper Sandler set a $6.50 target price on Neogen and gave the stock a “neutral” rating in a report on Thursday, October 16th. Finally, CJS Securities upgraded shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.83.

Neogen Trading Up 5.4%

Neogen stock opened at $7.47 on Friday. Neogen has a 12-month low of $3.87 and a 12-month high of $13.40. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.58 and a quick ratio of 2.26. The stock has a market capitalization of $1.62 billion, a PE ratio of -1.56 and a beta of 1.99. The firm has a 50 day simple moving average of $6.20 and a 200-day simple moving average of $5.65.

Institutional Investors Weigh In On Neogen

Several hedge funds have recently modified their holdings of the stock. Savant Capital LLC acquired a new position in shares of Neogen in the 2nd quarter valued at $50,000. Cresset Asset Management LLC acquired a new position in shares of Neogen in the second quarter worth about $53,000. Evergreen Capital Management LLC acquired a new position in shares of Neogen in the second quarter worth about $56,000. Blue Trust Inc. increased its position in shares of Neogen by 181.7% in the second quarter. Blue Trust Inc. now owns 11,974 shares of the company’s stock worth $57,000 after acquiring an additional 7,724 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Neogen by 183.5% during the second quarter. Osaic Holdings Inc. now owns 12,663 shares of the company’s stock valued at $61,000 after acquiring an additional 8,196 shares during the period. 96.73% of the stock is owned by hedge funds and other institutional investors.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.